The Elizabeth Glaser Pediatric AIDS Foundation has received a five-year, $9.7-million grant from the Bill & Melinda Gates Foundation to develop and test candidate vaccines to prevent HIV infection in children.
Deputy Secretary-General Asha-Rose Migiro will walk with a contingent of United Nations staff members and about 50,000 other people in the annual fundraiser called AIDS Walk New York on Sunday, a UN spokesman said today.
A vaccine that prevents HIV infection remains an important goal in the fight against AIDS, but the current top HIV vaccine candidates may not work in this way, say scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Using the new and highly publicized CDC guidelines for HIV screening, a university-based Emergency Department implemented opt-out screening in Washington, DC, where HIV infection rates are known to be high.
Fewer than one in every 10 injecting drug users have access to basic HIV prevention and treatment services, even though they comprise almost one third of new infections outside sub-Saharan Africa, according to the Joint UN Programme Against HIV/AIDS (UNAIDS).
Even though HIV can be well treated these days, drug users are still more cautious about using needles than they used to be. That is the conclusion of Colette Smit following her study into 25 years of HIV in the Netherlands.
May 18, 2007 marks the 10th annual HIV Vaccine Awareness Day, an opportunity to reflect upon the more than two decades of progress worldwide in the search for a safe and effective HIV vaccine.
The efforts of the Baylor International Pediatric AIDS Initiative expanded in a new direction with the opening of a state-of-the-art laboratory in partnership with and located at the Stefan S. Nicolau Institute of Virology in Bucharest, Romania.
Boehringer Ingelheim GmbH announced that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune? (nevirapine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), dosed once daily (QD) or twice daily (BID), versus atazanavir/ritonavir, a once-daily dosed protease inhibitor (PI).
Roche announced that the U.S. Food & Drug Administration (FDA) has approved its new HIV-1 test for diagnostic use in the United States. The highly accurate Cobas AmpliPrep/Cobas TaqMan HIV-1 Test is the first fully automated HIV-1 diagnostic tool using real-time PCR technology in the US.